CD274 and non-small cell lung carcinoma: The primary objectives of this investigation are to unveil alterations in the PD-L1 and miRNA expression profiles within exosomes in response to immunotherapeutic interventions, as well as to assess the viability of plasma exosomal PD-L1 and miRNAs as prospective biomarkers for predicting the therapeutic efficacy of anti-PD-1/PD-L1 treatment in NSCLC patients [85].